Heat Biologics

HTBX NASDAQ
0.6069
-0.0431
-6.63%
休市 16:00 07/19 EDT
开盘
0.6500
昨收
0.6500
最高
0.6500
最低
0.6000
成交量
19.21万
成交均量(3M)
29.79万
52周最高
2.330
52周最低
0.6000
换手率
0.56%
市值
2,067.44万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Heat Biologics HTBX股票价格,Heat Biologics股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
展开 >

最近浏览

名称
价格
涨跌幅